Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALEPRO: abemaciclib + letrozole in estrogen receptor-positive rare ovarian cancer
2023-503533-21-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of abemaciclib and letrozole in low-grade serous ovarian carcinoma (LGSOC), granulosa cell tumor (GCT) and Endometrioid Cystadenocarcinoma (2 arms), sponsored by UZ Leuven. Primary endpoint: Overall response rate. Planned start Nov 2023; status: authorised.
02
Drugs
abemaciclibletrozole
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)granulosa cell tumor (GCT)Endometrioid Cystadenocarcinoma
Beyond the preview
Go deeper on 2023-503533-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503533-21-00.